Fast Five Quiz: Type 2 Diabetes and Cardiovascular Disease Risk

Romesh Khardori, MD, PhD


February 15, 2022

Large randomized controlled trials have reported statistically significant reductions in cardiovascular events among patients receiving GLP-1 receptor agonists (liraglutide, semaglutide, and dulaglutide) and for those receiving the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin.

Cardiovascular outcomes trials of DPP-4 inhibitors have not shown cardiovascular benefits relative to placebo.

The ADA recently updated its guidelines to include consideration of atherosclerotic cardiovascular disease and kidney disease when choosing glucose-lowering therapies. Specifically:

DPP-4 inhibitors may lead to worsening heart failure in patients with established CVD or metabolic abnormalities.

Learn more about pharmacologic therapy for CVD risk reduction in patients with T2D.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.